Pall has a mature Business Continuity Management System, as well as a strong global and local infrastructure, to ensure minimal disruption to our business. In addition, Pall has implemented a comprehensive COVID–19 Pandemic Response Plan to minimize any impact to our customers, while protecting our associates and communities.
Pall prioritizes our associates’ health and well-being, as they safely work to manufacture and deliver essential products and services to customers. We take measures to prevent the spread of COVID–19 at our sites and promote social distancing.
Pall is participating in a consortium led by the Jenner Institute, University of Oxford (Oxford, England), to rapidly develop, scale-up and produce a vaccine for COVID–19. As part of the consortium, Pall will develop a large-scale manufacturing process, so that millions of doses of a vaccine can be produced. You can learn more here: Pall Corporation Participates In A Consortium To Rapidly Develop A COVID–19 Vaccine.
Need Immediate Assistance ?
Need Product Information ?
Product Specific frequently asked questions can be found on the product page. Please use the navigation, search bar or click below to help navigate to our products.